ClinicalTrials.gg
RecruitingNCT07216066Updated Sep 21, 2026

First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)

A Phase 1 interventional study of ALN-SNCA and Placebo in Parkinsons Disease, sponsored by Regeneron Pharmaceuticals. Recruiting at 3 sites in 2 countries. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 253 studies in Parkinson Disease with a site in Canada — 43 open to participants now, 62 under way, 3 of them phase 3. Parkinson Disease · Canada.

Planned enrollment
122nd of 212
46 · median 60
Started
2025
with 11 others
Phase 1
14 of 253
1 open now
Primary completion
2029-06
later than 57 of 61 live
Registered
243rd of 253
by date

Among the 253 studies in Parkinson Disease with a site in Canada, this one is the 122nd largest by planned enrollment of the 212 interventional ones that give a count, is one of 12 that started in 2025, is one of 14 in phase 1, reaches primary completion later than 57 of the 61 other live ones, and was the 243rd registered.

Parkinson Disease

4,581 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

43 of the 253 studies in Parkinson Disease with a site in Canada are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 253 studies in Parkinson Disease with a site in Canada, or all of them as a file.
02

Study summary

This study is researching an experimental drug called ALN-SNCA (called "study drug"). The study is focused on people with early Parkinson's disease, a disorder of the nervous system that affects movement. Parkinson's disease is caused by a gradual loss of nerve cells in the brain, especially those due to the harmful build-up of a protein called α-synuclein.

The aim of the study is to see if the study drug is safe and tolerated well enough to continue testing it in future studies and what side effects may happen from taking the study drug.

The study is looking at several other research questions, including:

  • Whether the study drug can lower the level of α-synuclein protein in the Cerebrospinal Fluid (also referred to as "CSF", the fluid that surrounds the brain and spinal cord)
  • How much study drug is in the blood, urine, and CSF at different times
03

Conditions studied

  • Parkinsons Disease

Keywords

  • Early Parkinsons disease
  • Motor and non-motor brain systems
  • Bradykinesia plus
  • Resting tremor
  • Rigidity
  • Postural instability
  • Cognitive impairment
  • Mood disorders
  • Sleep disturbances
  • Autonomic dysfunction
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosis of Parkinson's disease according to the Movement Disorder Society (MDS) criteria, as assessed by the investigator, with bradykinesia plus at least one of the other cardinal signs of Parkinson's disease (resting tremor, rigidity), without any other known or suspected cause of Parkinsonism
  2. A diagnosis of Parkinson's disease for 4 years or less at the screening visit
  3. Participant must meet one of the following criteria:

    1. Currently not receiving any standard-of-care (SoC) therapy for Parkinson's disease, has not been on oral dopaminergic therapy (ie, levodopa, dopamine agonists, or Monoamine Oxidase B [MAO-B] inhibitors) prior to dosing, and is not anticipated to require SoC therapy for Parkinson's disease within approximately 6 months following dosing, or
    2. Has been on a stable regimen of oral dopaminergic therapy for at least 3 months prior to dosing and is not anticipated to require dose adjustments within approximately 6 months following dosing
  4. ≤35 kg/m\^2 at time of screening visit

Key Exclusion Criteria:

  1. Medical history indicating a Parkinsonian syndrome other than Parkinson's disease, as defined in the protocol
  2. cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease (excluding Parkinson's disease) that, as assessed by the investigator, may confound the results of the study or pose an additional risk to the participant during study participation
  3. Medical history of brain or spinal disease/injury that would interfere with the Lumbar Puncture (LP) procedure or CSF circulation, as defined in the protocol
  4. Any to undergo a brain Magnetic Resonance Imaging (MRI)
  5. An established allergy or intolerance to lidocaine anesthetic, as defined in the protocol
  6. History of intolerance to Intrathecal (IT) injection(s)
  7. Current history of bleeding diatheses that would increase risk of bleeding upon LP
  8. Has undergone gene therapy, cell therapy or surgical treatment, including deep brain stimulation, for Parkinson's disease

NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    ALN-SNCA Dose Escalation

    Drug: ALN-SNCA

  • Placebo comparator
    Matching Placebo

    Drug: Placebo

Interventions

  • DrugALN-SNCA

    Administered per the protocol

  • DrugPlacebo

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Through Week 80

  2. Severity of TEAEs

    Time frame: Through Week 80

Secondary outcomes

  1. Concentration of alpha (a)-synuclein protein in CSF

    Time frame: Through Week 48

  2. Change from baseline in concentration of a-synuclein protein in CSF

    Time frame: Through Week 48

  3. Concentration of ALN-SNCA in plasma

    Time frame: Through Week 48

  4. Concentration of major metabolites in plasma

    Time frame: Through Week 48

  5. Concentration of ALN-SNCA in CSF

    Time frame: Through Week 48

  6. Concentration of major metabolites in CSF

    Time frame: Through Week 48

  7. Fraction [fc] of ALN-SNCA excreted in urine

    Time frame: Over 24 hours

  8. Fc of major metabolites excreted in urine

    Time frame: Over 24 hours

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2029, 42 months after the start.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 42 months is above that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2025
First posted
Oct 14, 2025
StartActual
Dec 5, 2025
Primary completionEst.
Jun 7, 2029
CompletionEst.
Jun 7, 2029
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07216066
Responsible party
Sponsor
First posted
Oct 14, 2025
Start date
Dec 5, 2025
Primary completion
Jun 7, 2029 (estimated)
Completion
Jun 7, 2029 (estimated)
Last update
Sep 21, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion